Juvenescence

LyGenesis, Inc. is a biotechnology company focused on organ regeneration, headquartered in Pittsburgh, Pennsylvania, and founded in 2017. The company has developed a pioneering technology that utilizes a patient's lymph nodes as bioreactors to facilitate the regrowth of ectopic organs. Its primary target for clinical development is liver regeneration, aimed at supporting individuals with end-stage liver disease. In addition to liver regeneration, LyGenesis is exploring therapeutic opportunities for other organs, including the thymus, pancreas, and kidney. The innovative approach enables surgeons to regrow functioning organs within a patient's own body, offering potential solutions for organ transplantation and regeneration.

Morphoceuticals is a biotechnology platform dedicated to advancing limb regeneration and regenerative interventions. The company focuses on understanding the biophysical mechanisms that govern decision-making in complex pattern regulation, utilizing bioelectric dynamics to influence developmental patterning and stimulate regeneration in organisms lacking natural regenerative capabilities. By leveraging bioelectric profiling, multi-omics, and artificial intelligence, Morphoceuticals aims to manipulate bioelectric signals to facilitate tissue repair and organ regeneration. This innovative approach supports medical researchers in addressing complex health challenges, including improving the health of amputation stumps, promoting organ regeneration, and treating channelopathies. Through its pioneering efforts, Morphoceuticals seeks to enhance the field of regenerative medicine and contribute to more effective treatment options for traumatic injuries.

MDI Therapeutics is a discovery stage pharmaceutical company dedicated to developing innovative therapies for fibrotic diseases and fibroproliferative disorders. The company has established a proprietary discovery platform that identifies novel small molecule and protein drug candidates. MDI Therapeutics advances these candidates through critical translational experiments utilizing clinical biomarkers. By focusing on serpin-based therapies, the company aims to provide healthcare providers with effective options to prevent and potentially reverse the fibrotic disease process, addressing a significant unmet medical need in the treatment of these conditions.

Portage Pharmaceuticals LTD. is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression, restore protein function, and improve medical outcomes. The Company has spun out its lead asset, PPL-003, to ophthalmic indications and has licensed this CellPorter technology to EyGen, a new ophthalmic company.

LyGenesis, Inc. is a biotechnology company focused on organ regeneration, headquartered in Pittsburgh, Pennsylvania, and founded in 2017. The company has developed a pioneering technology that utilizes a patient's lymph nodes as bioreactors to facilitate the regrowth of ectopic organs. Its primary target for clinical development is liver regeneration, aimed at supporting individuals with end-stage liver disease. In addition to liver regeneration, LyGenesis is exploring therapeutic opportunities for other organs, including the thymus, pancreas, and kidney. The innovative approach enables surgeons to regrow functioning organs within a patient's own body, offering potential solutions for organ transplantation and regeneration.

LyGenesis, Inc. is a biotechnology company focused on organ regeneration, headquartered in Pittsburgh, Pennsylvania, and founded in 2017. The company has developed a pioneering technology that utilizes a patient's lymph nodes as bioreactors to facilitate the regrowth of ectopic organs. Its primary target for clinical development is liver regeneration, aimed at supporting individuals with end-stage liver disease. In addition to liver regeneration, LyGenesis is exploring therapeutic opportunities for other organs, including the thymus, pancreas, and kidney. The innovative approach enables surgeons to regrow functioning organs within a patient's own body, offering potential solutions for organ transplantation and regeneration.

Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

BYOMass is developing therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses.

BHB Therapeutics is developing novel approaches to induce a state of ketosis, which may have protective effects against age-related disease.

AgeX Therapeutics, Inc. is a biotechnology company based in Alameda, California, specializing in the development and commercialization of innovative therapeutics aimed at addressing human aging and degenerative diseases. The company harnesses proprietary technologies, including telomerase-mediated cell immortality and induced Tissue Regeneration, to create novel treatments. Its product pipeline features two primary cell-based candidates: AGEX-BAT1, which targets age-related metabolic disorders such as Type II diabetes, and AGEX-VASC1, designed to restore vascular support in ischemic tissues. Additionally, AgeX is working on AGEX-iTR1547, a drug formulation intended to enhance regenerative potential in aged tissues suffering from degenerative conditions. The company also offers human embryonic stem cells and a suite of genomic interpretation tools for researchers. AgeX has collaborated with the University of California, Irvine, on neural stem cell research related to Huntington's disease and other neurological disorders. Founded in 2017, AgeX continues to advance its mission of addressing the challenges associated with aging.

Napa Therapeutics is a biotechnology company focused on a novel target linked to one of the fundamental processes of aging. A privately held British Virgin Islands company with an office in the Isle of Man, Napa is developing small molecule drugs to address this target.

FoxBio is a developer of a small molecules techniques intended to reduce senescent cells in human bodies. The company's techniques targets the pro-survival pathways of senescent cells to remove them from the body, enabling patients to have multiple health benefits and delay the onset of age related diseases.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

AgeX Therapeutics, Inc. is a biotechnology company based in Alameda, California, specializing in the development and commercialization of innovative therapeutics aimed at addressing human aging and degenerative diseases. The company harnesses proprietary technologies, including telomerase-mediated cell immortality and induced Tissue Regeneration, to create novel treatments. Its product pipeline features two primary cell-based candidates: AGEX-BAT1, which targets age-related metabolic disorders such as Type II diabetes, and AGEX-VASC1, designed to restore vascular support in ischemic tissues. Additionally, AgeX is working on AGEX-iTR1547, a drug formulation intended to enhance regenerative potential in aged tissues suffering from degenerative conditions. The company also offers human embryonic stem cells and a suite of genomic interpretation tools for researchers. AgeX has collaborated with the University of California, Irvine, on neural stem cell research related to Huntington's disease and other neurological disorders. Founded in 2017, AgeX continues to advance its mission of addressing the challenges associated with aging.

LyGenesis, Inc. is a biotechnology company focused on organ regeneration, headquartered in Pittsburgh, Pennsylvania, and founded in 2017. The company has developed a pioneering technology that utilizes a patient's lymph nodes as bioreactors to facilitate the regrowth of ectopic organs. Its primary target for clinical development is liver regeneration, aimed at supporting individuals with end-stage liver disease. In addition to liver regeneration, LyGenesis is exploring therapeutic opportunities for other organs, including the thymus, pancreas, and kidney. The innovative approach enables surgeons to regrow functioning organs within a patient's own body, offering potential solutions for organ transplantation and regeneration.